For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Complete and Sustained Objective Response per RECIST to Irvalec (PM02734) in Undifferentiated Large Cell Esophageal Adenocarcinoma: A Case Report and a Review of the LiteratureSalazar R.a · Cuadra C.a · Gil-Martín M.a · Vandermeeren A.b · Alfaro V.b · Coronado C.b
aInstituto Catalán de Oncología-IDIBELL, Barcelona, and bPharmaMar, Colmenar Viejo, Spain Corresponding Author
Ramón Salazar, MD
Instituto Catalán de Oncología-IDIBELL
Avda. Gran Via 199–203
ES–08907 L’Hospitalet de Llobregat, Barcelona (Spain)
Tel. +34 93 260 7739, E-Mail firstname.lastname@example.org
Undifferentiated large cell carcinoma is a rare entity in esophageal cancer and very few data are available in the literature on this uncommon histological subtype. We report a case of a 58-year-old Caucasian male previously treated with cisplatin/5-fluorouracil, docetaxel and carboplatin/plitidepsin who received treatment with a novel antitumor agent, Irvalec (PM02734), as fourth line. The patient received treatment from July 2006 to July 2009, a total of 49 cycles, at a dose of 2.4 mg/m2 as a 24-hour infusion every 3 weeks. He did not present severe complications or unplanned or cumulative toxicities. Complete and durable response according to RECIST was reported. He was alive at the last follow-up on March 2012.
© 2012 S. Karger AG, Basel